Five peptide reports with more than twice the stated amount

Five reported overfills

The table ranks five selected compound examples by percentage above the stated amount. Every link opens the original Freedom Diagnostics report; the names underneath are its printed clients. All dates are in 2026.

*ACE-031 is the reported mean of two samples: 6.01 and 6.19 mg. The other rows use the report's stated net-content result. These are report comparisons, not five independently purchased retail vials.

What the tesamorelin and CJC-1295 reports establish

The tesamorelin result is 2.694 times its stated amount. Both numbers appear in the original report, but it contains no vial photograph. Its denominator is therefore the report’s 5 mg description, without an independently readable label.

The CJC-1295 report and its vial photograph both say 5 mg. Neither identifies the DAC form, so we retain that uncertainty. A separate, explicitly labeled CJC-1295 without DAC report, dated September 15, measures 10.22 mg against 5 mg. It supports a similar comparison for that named form; it does not resolve the Estera sample’s identity.

The GHK-Cu report describes raw blue crystallized powder. Its unusually large ratio should not be generalized to ordinary GHK-Cu products. Likewise, the two ACE-031 samples are averaged: adding their contents together would create a false, larger overfill.

Why a dramatic number needs a source check

Some apparent leaders disappear when the documents are compared. One Pep Haus tirzepatide report calls the product 10 mg, while its vial photograph clearly says 30 mg. Its measured 32.23 mg is 7.4% above the photographed strength, rather than the apparent 222.3% above the report’s product field. We excluded that conflicting comparison.

A laboratory measurement above a stated amount can reflect physical overfill, a mislabeled sample, a submission mistake or a reporting error. The certificates alone do not establish which explanation applies. We use overfill here for the reported content difference; a clinical overdose would require evidence about what someone actually received or took.

Method and evidence boundary

We screened TitrateLab’s collected reports dated April 29–October 29, 2026, then selected large, source-checkable comparisons for five compounds, including tesamorelin and CJC-1295. This is an illustrative shortlist, not an exhaustive market ranking. All five selected originals are from Freedom Diagnostics; selection and publication are nonrandom.

The calculation is 100 × (measured amount ÷ stated amount − 1). We checked original PDFs, available vial photographs, matching units, repeated reports and conflicting strengths. Unresolved units, concentration-versus-total comparisons and identifiable duplicate results were excluded. Public report links above expose the supporting evidence; our underlying curated corpus remains proprietary.

An extreme result and a frequent result answer different questions. Our compound-level overfill comparison examines frequency with explicit denominators. For an individual certificate, use the COA reading guide to inspect quantity alongside identity, purity and the stated strength.

Prepared by the TitrateLab Research Desk with AI-assisted data analysis and editorial tooling; sources reviewed October 29, 2026. TitrateLab collected these reports and did not perform the assays. Send a source or calculation correction, including the report number.